Eosinophils and disease pathogenesis

Seminars in Hematology

Volumn 49, Issue 2, 2012, Pages 113-119

  Akuthota, Praveen ^a   Weller, Peter F ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; EOSINOPHIL PROTEIN X; EOTAXIN; EOTAXIN 2; EOTAXIN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEPOLIZUMAB; PROTEIN C; THROMBOMODULIN; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC DISEASE; ARTICLE; ASTHMA; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CHURG STRAUSS SYNDROME; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; FIBROSING ALVEOLITIS; FIBROSIS; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCOAGULABILITY; HYPEREOSINOPHILIC SYNDROME; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TH2 CELL;

ANIMALS; EOSINOPHILS; FIBROSIS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFLAMMATION; TH2 CELLS; THROMBOPHILIA;

EID: 84858785560     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.01.005     Document Type: Article

References (84)

1. Sanderson C.J., Warren D.J., Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J Exp Med 1985, 162:60-74.
2. Clutterbuck E.J., Sanderson C.J. Human eosinophil hematopoiesis studied in vitro by means of murine eosinophil differentiation factor (IL5): production of functionally active eosinophils from normal human bone marrow. Blood 1988, 71:646-651.
3. Yamaguchi Y., Suda T., Suda J., et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988, 167:43-56.
4. Warringa R.A., Schweizer R.C., Maikoe T., Kuijper P.H., Bruijnzeel P.L., Koendermann L. Modulation of eosinophil chemotaxis by interleukin-5. Am J Respir Cell Mol Biol 1992, 7:631-636.
5. Yamaguchi Y., Hayashi Y., Sugama Y., et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 1988, 167:1737-1742.
6. Kita H., Weiler D.A., Abu-Ghazaleh R., Sanderson C.J., Gleich G.J. Release of granule proteins from eosinophils cultured with IL-5. J Immunol 1992, 149:629-635.
7. Weller P.F., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
8. Hamid Q., Azzawi M., Ying S., et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991, 87:1541-1546.
9. Hellmich B., Csernok E., Gross W.L. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci 2005, 1051:121-131.
10. Assa'ad A.H., Gupta S.K., Collins M.H., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011, 141:1593-1604.
11. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
12. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
13. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
14. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2011, 125:1336-1343.
15. Kitamura T., Sato N., Arai K., Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 1991, 66:1165-1174.
16. Tavernier J., Devos R., Cornelis S., et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991, 66:1175-1184.
17. Tai P.C., Sun L., Spry C.J. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 1991, 85:312-316.
18. Sun Q., Jones K., McClure B., et al. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Blood 1999, 94:1943-1951.
19. Park C.S., Choi Y.S., Ki S.Y., et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J 1998, 12:872-878.
20. Rothenberg M.E., Owen W.F., Silberstein D.S., et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988, 81:1986-1992.
21. Tai P.C., Spry C.J. The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils. Clin Exp Immunol 1990, 80:426-434.
22. Sung K.L., Li Y., Elices M., Gang J., Sriramarao P., Broide D.H. Granulocyte-macrophage colony-stimulating factor regulates the functional adhesive state of very late antigen-4 expressed by eosinophils. J Immunol 1997, 158:919-927.
23. Horiuchi T., Weller P.F. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997, 17:70-77.
24. Lucey D.R., Nicholson-Weller A., Weller P.F. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A 1989, 86:1348-1351.
25. Akuthota P., Wang H.B., Spencer L.A., Weller P.F. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin Exp Allergy 2008, 38:1254-1263.
26. Kita H., Ohnishi T., Okubo Y., Weiler D., Abrams J.S., Gleich G.J. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991, 174:745-748.
27. Bandeira-Melo C., Herbst A., Weller P.F. Eotaxins. Contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 2001, 24:653-657.
28. Adamko D., Lacy P., Moqbel R. Mechanisms of eosinophil recruitment and activation. Curr Allergy Asthma Rep 2002, 2:107-116.
29. Stein M.L., Villanueva J.M., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008, 121:1473-1483.
30. Broekema M., Timens W., Vonk J.M., et al. Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. Am J Respir Crit Care Med 2011, 183:310-316.
31. Leiferman K.M. Eosinophils in atopic dermatitis. J Allergy Clin Immunol 1994, 94:1310-1317.
32. Simon D., Wardlaw A., Rothenberg M.E. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol 2010, 126:3-13.
33. Adame J., Cohen P.R. Eosinophilic panniculitis: diagnostic considerations and evaluation. J Am Acad Dermatol 1996, 34:229-234.
34. Caputo R., Marzano A.V., Vezzoli P., Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol 2006, 142:1157-1161.
35. Doyle J.A., Ginsburg W.W. Eosinophilic fasciitis. Med Clin North Am 1989, 73:1157-1166.
36. Gleich G.J., Schroeter A.L., Marcoux J.P., Sachs M.I., O'Connell E.J., Kohler P.F. Episodic angioedema associated with eosinophilia. N Engl J Med 1984, 310:1621-1626.
37. Wechsler M.E. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:477-492.
38. Liacouras C.A., Furuta G.T., Hirano I., et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011, 128:3-20.
39. Noguchi H., Kephart G.M., Colby T.V., Gleich G.J. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992, 140:521-528.
40. Pincus S.H., Ramesh K.S., Wyler D.J. Eosinophils stimulate fibroblast DNA synthesis. Blood 1987, 70:572-574.
41. Levi-Schaffer F., Garbuzenko E., Rubin A., et al. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci U S A 1999, 96:9660-9665.
42. Wong D.T., Elovic A., Matossian K., et al. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood 1991, 78:2702-2707.
43. Shock A., Rabe K.F., Dent G., et al. Eosinophils adhere to and stimulate replication of lung fibroblasts 'in vitro'. Clin Exp Immunol 1991, 86:185-190.
44. Zagai U., Skold C.M., Trulson A., Venge P., Lundahl J. The effect of eosinophils on collagen gel contraction and implications for tissue remodelling. Clin Exp Immunol 2004, 135:427-433.
45. Zagai U., Dadfar E., Lundahl J., Venge P., Skold C.M. Eosinophil cationic protein stimulates TGF-beta1 release by human lung fibroblasts in vitro. Inflammation 2007, 30:153-160.
46. Gomes I., Mathur S.K., Espenshade B.M., Mori Y., Varga J., Ackerman S.J. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 2005, 116:796-804.
47. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
48. Levi-Schaffer F., Weg V.B. Mast cells, eosinophils and fibrosis. Clin Exp Allergy 1997, 27(Suppl 1):64-70.
49. Patel A.K., D'Arbela P.G., Somers K. Endomyocardial fibrosis and eosinophilia. Br Heart J 1977, 39:238-241.
50. Ogbogu P.U., Rosing D.R., Horne M.K. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007, 27:457-475.
51. Bain B.J., Fletcher S.H. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007, 27:377-388.
52. Sinister eosinophils and the heart. Lancet 1977, 1:943.
53. Hallgren R., Bjermer L., Lundgren R., Venge P. The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis 1989, 139:373-377.
54. Fujimoto K., Kubo K., Yamaguchi S., Honda T., Matsuzawa Y. Eosinophil activation in patients with pulmonary fibrosis. Chest 1995, 108:48-54.
55. Birring S.S., Parker D., McKenna S., et al. Sputum eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res 2005, 54:51-56.
56. Huaux F., Liu T., McGarry B., Ullenbruch M., Xing Z., Phan S.H. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol 2003, 171:5470-5481.
57. Aceves S.S., Broide D.H. Airway fibrosis and angiogenesis due to eosinophil trafficking in chronic asthma. Curr Mol Med 2008, 8:350-358.
58. Minshall E.M., Leung D.Y., Martin R.J., et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997, 17:326-333.
59. Torrego A., Hew M., Oates T., Sukkar M., Fan Chung K. Expression and activation of TGF-beta isoforms in acute allergen-induced remodelling in asthma. Thorax 2007, 62:307-313.
60. Balzar S., Chu H.W., Silkoff P., et al. Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol 2005, 115:110-117.
61. Tanaka H., Komai M., Nagao K., et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 2004, 31:62-68.
62. Humbles A.A., Lloyd C.M., McMillan S.J., et al. A critical role for eosinophils in allergic airways remodeling. Science 2004, 305:1776-1779.
63. Flood-Page P., Menzies-Gow A., Phipps S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003, 112:1029-1036.
64. Aceves S.S., Ackerman S.J. Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am 2009, 29:197-211.
65. Aceves S.S., Newbury R.O., Dohil R., Bastian J.F., Broide D.H. Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2007, 119:206-212.
66. Narayan S., Ezughah F., Standen G.R., Pawade J., Kennedy C.T. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol 2003, 148:817-820.
67. Terrier B., Piette A.M., Kerob D., et al. Superficial venous thrombophlebitis as the initial manifestation of hypereosinophilic syndrome: study of the first 3 cases. Arch Dermatol 2006, 142:1606-1610.
68. Liapis H., Ho A.K., Brown D., Mindel G., Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 2005, 67:1806-1811.
69. Kanno H., Ouchi N., Sato M., Wada T., Sawai T. Hypereosinophilia with systemic thrombophlebitis. Hum Pathol 2005, 36:585-589.
70. Vazquez J.J., Fernandez Pavon A., Arnalich F., et al. Coagulation abnormalities in patients with eosinophilia. Postgrad Med J 1987, 63:943-945.
71. Venge P., Zetterstrom O., Dahl R., Roxin L.E., Olsson I. Low levels of eosinophil cationic proteins in patients with asthma. Lancet 1977, 2:373-375.
72. Rohrbach M.S., Wheatley C.L., Slifman N.R., Gleich G.J. Activation of platelets by eosinophil granule proteins. J Exp Med 1990, 172:1271-1274.
73. Slungaard A., Vercellotti G.M., Tran T., Gleich G.J., Key N.S. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993, 91:1721-1730.
74. Samoszuk M., Corwin M., Hazen S.L. Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting. Am J Hematol 2003, 73:18-25.
75. Wang J.G., Mahmud S.A., Thompson J.A., Geng J.G., Key N.S., Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006, 107:558-565.
76. Moosbauer C., Morgenstern E., Cuvelier S.L., et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007, 109:995-1002.
77. Akuthota P., Xenakis J.J., Weller P.F. Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity?. J Innate Immun 2011, 3:113-119.
78. Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev 2011, 242:161-177.
79. Spencer L.A., Szela C.T., Perez S.A., et al. Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol 2009, 85:117-123.
80. Roth N., Stadler S., Lemann M., et al. Distinct eosinophil cytokine expression patterns in skin diseases-the possible existence of functionally different eosinophil subpopulations. Allergy 2011, 66:1477-1486.
81. Johnsson M., Bove M., Bergquist H., et al. Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy. J Innate Immun 2011, 3:594-604.
82. Wang H.B., Ghiran I., Matthaei K., Weller P.F. Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol 2007, 179:7585-7592.
83. Foster E.L., Simpson E.L., Fredrikson L.J., et al. Eosinophils increase neuron branching in human and murine skin and in vitro. PLoS One 2011, 6:e22029.
84. Verbout N.G., Jacoby D.B., Gleich G.J., Fryer A.D. Atropine-enhanced, antigen challenge-induced airway hyperreactivity in guinea pigs is mediated by eosinophils and nerve growth factor. Am J Physiol Lung Cell Mol Physiol 2009, 297:L228-L237.